H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $10 from $9 and keeps a Buy rating on the shares. The firm says Papzimeos sales are expected to exceed $18M in Q1. It cites positive early launch metrics for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN: